Recombinant Human Antibody (KZ52 ) is capable of binding to EBOV GP, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-EBOV GP mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-EBOV GP proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Figure 1 Reactivity of human anti-Ebola virus Fab KZ52 with a γ-irradiated whole-virion preparation (open squares) and with irradiated crude infected-cell supernatants (solid circles) determined by ELISA.
Ovalbumin (4 μg/ml) is included as a control antigen (open diamonds). OD405, optical density at 405 nm.
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., ... & Burton, D. R. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of virology, 73(7), 6024-6030.
Figure 2 Reactivity of anti-Ebola virus Fabs with live and fixed Ebola virus-infected Vero E6 cells shown by immunofluorescence.
Staining is shown for Fab KZ52 on live (A) and fixed (D) Ebola virus-infected cells, for Fab LZ51 on live (B) and fixed (E) Ebola virus-infected cells, and for ELZ510 on live (C) and fixed (F) Ebola virus-infected cells.
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., ... & Burton, D. R. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of virology, 73(7), 6024-6030.
Figure 3 Longer-exposure autoradiograms obtained to reveal the immunoprecipitation of Fab KZ52 to GP2.
Exposure of autoradiograms for 2.5 months (compared to 1 week for panel B) reveals immunoprecipitation of a band corresponding to GP2 by Fab KZ52 from Ebola virus-infected cell supernatants (lanes 1) and from crude infected-cell supernatants (lanes 2). Lanes 3 is uninfected-cell supernatant controls.
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., ... & Burton, D. R. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of virology, 73(7), 6024-6030.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-298-S(P) | Recombinant Human Anti-EBOV GP Antibody scFv Fragment | WB, IF, FuncS | scFv |
PSBW-038 | Recombinant Mouse Anti-EBOV GP Antibody scFv Fragment (14G7) | ELISA, Neut | scFv |
HPAB-1098WJ-S(P) | Mouse Anti-EBOV GP Recombinant Antibody; scFv Fragment (HPAB-1098WJ-S(P)) | ELISA, WB | Mouse scFv |
PABJ-0009-S(P) | Human Anti-EBOV GP Recombinant Antibody scFv Fragment (PABJ-0009-S(P)) | ELISA, Neut | Human scFv |
PSBS-0002 | Human Anti-Ebola virus glycoprotein Recombinant Antibody scFv Fragment (PSBS-0002) | ELISA, Neut, FuncS | Human scFv |
There are currently no Customer reviews or questions for PABL-458. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.